Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
When surgery and/or radiation therapy for laBCC or mBCC is not reasonable, oral hedgehog inhibitor (HHI) therapy may be initiated.
Damsin et al. 2022 Expert Review of Anticancer Therapy, 22(3): 243-248
LaBCC or mBCC patients with primary or secondary resistance, progression, or intolerance to HHIs could benefit from programmed cell death protein-1 (PD-1) inhibitors. This was recently published for cemiplimab, a recombinant IgG4 human monoclonal antibody anti-PD-1 for the intravenous treatment of laBCC and mBCC.
Damsin et al. 2022 Expert Review of Anticancer Therapy, 22(3): 243-248…